Single-course gene-editing therapy CTX310 lowers triglycerides by 63% in severe hypertriglyceridemia – CRISPR Therapeutics
CRISPR Therapeutics has presented Phase 1b data for CTX310 in patients with severe hypertriglyceridemia (sHTG) in a late-breaking oral presentation at the AHA Scientific Sessions 2026. CTX310 is an investigational in vivo CRISPR/Cas9 gene-editing therapy that targets angiopoietin-like protein 3 (ANGPTL3). It is delivered to the liver using a lipid nanoparticle.
Study design
The Phase 1b study is multicentre and open-label. In the sHTG cohort, 10 participants with fasting triglycerides above 500 mg/dL received a single IV infusion of CTX310 at a flat dose: 40 mg for people weighing under 85 kg, or 50 mg for those weighing 85 kg or more. This dosing approximates the 0.8 mg/kg dose used in Phase 1a. The cohort also includes one Phase 1a participant who received 56.5 mg. The trial is enrolling in New Zealand, Australia, the UK and the US.
At baseline, median triglycerides were above 1,000 mg/dL. All participants had diabetes, 30% had a history of pancreatitis and 20% had clinical atherosclerotic cardiovascular disease.
Results at Day 30
- Circulating ANGPTL3 fell by a mean of 65%
- Triglycerides fell by a mean of 63%
- Non-HDL cholesterol fell by 51%, apolipoprotein B by 23%, and LDL cholesterol by 16% (from a low mean baseline of 60 mg/dL)
The reductions in ANGPTL3 and triglycerides were maintained in participants followed for at least 90 days. No acute pancreatitis was reported.
Safety
Seven participants had been followed for at least 90 days at data cutoff. There were no CTX310-related serious adverse events and no clinically relevant rises in AST or ALT. One participant had a Grade 2 infusion-related reaction, which resolved, and they were able to complete the infusion.
“These results are promising and represent a new pathway for lipid management, with the potential of a one-time treatment to address multiple lipid disorders that remain difficult to control with current therapies,” said Ashish Sarraju, MD, a preventive cardiologist at Cleveland Clinic, who presented the data.
The data build on the Phase 1a results, including one-year durability data presented at ESC Congress 2026 and published in The New England Journal of Medicine. The FDA recently granted CTX310 Regenerative Medicine Advanced Therapy (RMAT) designations for sHTG and for elevated LDL cholesterol. Further Phase 1b cohorts across other lipid disorders are ongoing.




